Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Marovt, Maruška; Marko, Pij Bogomir

doi:10.1177/2050313x211034926

Cited by 3 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apremilast is a small-molecule inhibitor of phosphodiesterase (PDE) 4 that is currently approved for the treatment of plaque psoriasis and psoriatic arthritis. There are limited case reports that demonstrate the therapeutic potential of apremilast for patients with PPPP and GPP [46][47][48]. APLANTUS was a 20-week, phase II open-label study that investigated the efficacy and safety of apremilast in patients with PPPP [14].…”

Section: Treatmentmentioning

confidence: 99%

Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis

et al. 2021

View full text Add to dashboard Cite

The similarity between pustular psoriasis (PP) and acute generalized exanthematous pustulosis (AGEP) poses problems in the diagnosis and treatment of these two conditions. Significant clinical and histopathologic overlap exists between PP and AGEP. PP is an inflammatory disorder that has numerous clinical subtypes, but all with sterile pustules composed of neutrophils. AGEP is a severe cutaneous adverse reaction that is also characterized by non-follicular sterile pustules. Clinical features that suggest a diagnosis of PP over AGEP include a history of psoriasis and the presence of scaling plaques. Histologically, eosinophilic spongiosis, vacuolar interface dermatitis, and dermal eosinophilia favor a diagnosis of AGEP over PP. Importantly, PP and AGEP vary in clinical course and treatment. PP treatment involves topical steroids, oral retinoids, and systemic immunosuppressants. Newer therapies targeting IL-36, IL-23, IL-1, and PDE-4 have been investigated. The removal of the offending agent is a crucial part of the treatment of AGEP.

show abstract

Section: Treatmentmentioning

confidence: 99%

Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Mean lengths of treatment for apremilast and tofacitinib were also similar to those for biologics; topical medications had the shortest treatment lengths. These oral therapies may be more cost-effective alternatives to biologic treatment [ 30 , 31 ]. In the US, phototherapy appears to be used sparingly to treat patients with PPP, and treatment patterns across different phototherapy options were similar, with most patients discontinuing treatment within a year.…”

Section: Discussionmentioning

confidence: 99%

Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US

Cheng,

Deng,

Yang

et al. 2024

Dermatol Ther (Heidelb)

View full text Add to dashboard Cite

Introduction Limited information exists on the epidemiology, treatment, and burden of palmoplantar pustulosis (PPP) and defining the optimal course of treatment remains challenging without approved targeted treatments in most countries. Here, we describe the clinical and demographic characteristics, treatments received, and negative health outcomes experienced among patients with PPP in the United States (US) and Germany. Methods Retrospective cohort study between 2016 and 2021 using data from the US Merative™ MarketScan® Research Database and IQVIA™ German Disease Analyzer. Adult patients with PPP (ICD-10-CM L40.3) were followed from the date of their first qualifying PPP diagnosis and continued until the earlier of disenrollment or end date of database, during which treatment patterns and incidence rates of negative health outcomes were assessed. Treatment patterns included adherence, non-persistence, discontinuation, re-initiation, switching, and combination therapy. Results The prevalence of PPP was 0.005% and 0.065% in the MarketScan database and German Disease Analyzer, respectively, with 1629 and 3866 patients meeting the inclusion criteria. Most patients were female (71.3%, 67.8%), with mean (SD) age of 54.1 (11.7) and 56.9 (14.3) years, respectively. One year post index, most patients received topical treatment (77.4%, 65.3%), but non-persistence and discontinuation were high. Oral and biologic treatments displayed higher levels of adherence, particularly apremilast and tofacitinib among oral treatments and TNF inhibitors and IL-23 inhibitors among biologics. Rates of negative health outcomes were higher among patients not receiving treatment post-index compared with those receiving treatment post-index across both databases, regardless of prior treatment history. Conclusions Establishing treatment guidelines remains an unmet need for patients with PPP and could improve quality of life by reducing the occurrence of negative health outcomes. The findings from this study may provide insight into the effectiveness of current treatment options for patients with PPP and can be leveraged to support the development of treatment guidelines. Supplementary Information The online version contains supplementary material available at 10.1007/s13555-024-01109-z.

show abstract

An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations

Wang

Jin

2023

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Apremilast monotherapy for palmoplantar pustulosis: Report of three cases

Cited by 3 publications

References 10 publications

Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis

Pustular Psoriasis and Acute Generalized Exanthematous Pustulosis

Treatment Patterns and Negative Health Outcomes in Palmoplantar Pustulosis Patients in Germany and the US

An update on therapeutic options for palmoplantar pustulosis: a narrative review and expert recommendations

Contact Info

Product

Resources

About